To view this email as a web page, click here.
 
FDA approves revolutionary blood cancer treatment
FDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma is the first new advanced treatment for the disease in 40 years.
Read more
 
Compounding facilities face new FDA regs
Due to problems with compounded medications, FDA is releasing a draft guidance that will determine which bulk drug substances outsourcing facilities can use to compound drugs.
Read more
 
Pharma makers pull MS drug from worldwide market
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.